Literature DB >> 6204797

Adoptive transfer of delayed type hypersensitivity reactions specific for Leishmania major antigens to normal mice using murine T cell populations and clones generated in vitro.

G C Lima, H D Engers, J A Louis.   

Abstract

Leishmania major specific murine T cell blasts and clones maintained in vitro were tested for their ability to adoptively transfer delayed type hypersensitivity (DTH) reactions to normal mice. These effector cells exhibited a Lyt 1+2- cell surface phenotype. They induced specific DTH reactions in syngeneic DBA/2 mice after local transfer in the footpad, (together with parasite antigens) or intravenous injection followed by challenge with parasite antigens in the footpad. The DTH reactions were specific for L. major antigens and required H-2 identity between the injected T cells (clones) and the adoptively transferred host. Using radioactively labelled T cell blasts for intravenous transfer, it was demonstrated that a large fraction of these functionally active cells localized in the spleen and footpad which had been challenged with parasite antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204797      PMCID: PMC1536093     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Role of major histocompatibility complex gene products in delayed-type hypersensitivity.

Authors:  J F Miller; M A Vadas; A Whitelaw; J Gamble
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

2.  Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC.

Authors:  J E Ryser; J C Cerottini; K T Brunner
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

3.  Protective activity of secondary effector T cells generated in vitro against ectromelia virus infection in vivo.

Authors:  U Kees; R V Blanden
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

4.  Immunity in cutaneous leishmaniasis of the guinea-pig.

Authors:  A D Bryceson; R S Bray; R A Wolstencroft; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1970-09       Impact factor: 4.330

5.  Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host.

Authors:  J Convit; M E Pinardi; A J Rondón
Journal:  Trans R Soc Trop Med Hyg       Date:  1972       Impact factor: 2.184

6.  H-2 gene complex restricts transfer of delayed-type hypersensitivity in mice.

Authors:  J F Miller; M A Vadas; A Whitelaw; J Gamble
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

7.  Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice.

Authors:  G Corradin; H M Etlinger; J M Chiller
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

8.  Cell-mediated immunity: delayed-type hypersensitivity and cytotoxic responses are mediated by different T-cell subclasses.

Authors:  B Huber; O Devinsky; R K Gershon; H Cantor
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

9.  Ly and Ia antigen phenotypes of T cells involved in delayed-type hypersensitivity and in suppression.

Authors:  M A Vadas; J F Miller; I F McKenzie; S E Chism; F W Shen; E A Boyse; J R Gamble; A M Whitelaw
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

10.  Independent populations of primed F1 guinea pig T lymphocytes respond to antigen-pulsed parental peritoneal exudate cells.

Authors:  W E Paul; E M Shevach; S Pickeral; D W Thomas; A S Rosenthal
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

View more
  1 in total

1.  New Zealand black mice are immunologically resistant to high-dose, but not low-dose Leishmania mexicana infection.

Authors:  R C Dorea; J Alexander; G Gallagher
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.